Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression.
Luke Paul Akard
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; Millennium; Novartis; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Teva
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Franck E. Nicolini
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - Novartis
Meir Wetzler
Consultant or Advisory Role - Teva
Research Funding - Bristol-Myers Squibb
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Stock Ownership - ARIAD
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
No relevant relationships to disclose
Adam Craig
Consultant or Advisory Role - Teva
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer